Transforms MRI technology into a platform for quantitative biomarker assessment, enabling objective clinical decision-making. This approach standardizes and quantifies imaging data, providing healthcare professionals with measurable insights to improve diagnosis and treatment strategies.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional MRI interpretation relies on subjective visual assessment, leading to variability and limiting the ability to track subtle changes in disease progression. This subjectivity hinders objective clinical decision-making and the development of quantitative biomarkers.
Solution
Stratagen Bio is developing a platform to transform MRI technology into a source of quantitative biomarker assessment, enabling objective clinical decision-making. The platform aims to standardize and quantify imaging data, providing healthcare professionals with measurable insights. By applying advanced image processing and analysis techniques, the platform extracts meaningful biomarkers from MRI scans, facilitating improved diagnosis, treatment planning, and monitoring of disease progression. This quantitative approach reduces reliance on subjective interpretation and enhances the precision of clinical assessments.
Target Audience
The primary target audience includes radiologists, neurologists, oncologists, and other healthcare professionals who utilize MRI in their clinical practice, as well as pharmaceutical companies and research institutions involved in clinical trials.
Features
- Advanced image processing algorithms for automated segmentation and quantification of anatomical structures.
- Proprietary methods for extracting and analyzing quantitative biomarkers from MRI data.
- Standardized reporting templates for consistent and objective presentation of imaging results.